A detailed history of Bank Of Montreal transactions in Ironwood Pharmaceuticals Inc stock. As of the latest transaction made, Bank Of Montreal holds 13,669 shares of IRWD stock, worth $60,827. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,669
Previous 94,564 85.55%
Holding current value
$60,827
Previous $616,000 90.91%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$3.93 - $7.04 $317,917 - $569,500
-80,895 Reduced 85.55%
13,669 $56,000
Q2 2024

Aug 14, 2024

BUY
$5.58 - $8.61 $448,168 - $691,529
80,317 Added 563.75%
94,564 $616,000
Q1 2024

May 13, 2024

BUY
$8.32 - $15.45 $5,524 - $10,258
664 Added 4.89%
14,247 $124,000
Q4 2023

Feb 08, 2024

BUY
$8.79 - $11.51 $24,058 - $31,502
2,737 Added 25.24%
13,583 $155,000
Q3 2023

Nov 01, 2023

SELL
$8.25 - $11.35 $45,391 - $62,447
-5,502 Reduced 33.66%
10,846 $104,000
Q2 2023

Aug 02, 2023

BUY
$10.1 - $11.6 $28,421 - $32,642
2,814 Added 20.79%
16,348 $173,000
Q1 2023

Jun 13, 2024

BUY
$10.37 - $12.56 $37,446 - $45,354
3,611 Added 25.35%
17,858 $187,000
Q4 2022

Feb 01, 2023

SELL
$9.9 - $12.43 $1,059 - $1,330
-107 Reduced 0.78%
13,534 $167,000
Q3 2022

Nov 10, 2022

SELL
$10.14 - $12.38 $21,010 - $25,651
-2,072 Reduced 13.19%
13,641 $143,000
Q2 2022

Aug 11, 2022

BUY
$11.05 - $12.72 $156,755 - $180,445
14,186 Added 929.01%
15,713 $193,000
Q1 2022

May 12, 2022

BUY
$10.61 - $12.88 $16,201 - $19,667
1,527 New
1,527 $19,000
Q4 2021

Feb 11, 2022

SELL
$10.86 - $13.95 $16,637 - $21,371
-1,532 Closed
0 $0
Q2 2021

Aug 12, 2021

BUY
$10.16 - $13.11 $15,565 - $20,084
1,532 New
1,532 $20,000

Others Institutions Holding IRWD

About IRONWOOD PHARMACEUTICALS INC


  • Ticker IRWD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 153,231,008
  • Market Cap $682M
  • Description
  • Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZE...
More about IRWD
Track This Portfolio

Track Bank Of Montreal Portfolio

Follow Bank Of Montreal and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of Montreal , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of Montreal with notifications on news.